| ACh | Acetylcholine |
| Akt | Protein kinase B |
| Apamin | Small conductance calcium-activated potassium channel inhibitor |
| ANX-A | Annexin A1, endogenous ligand for FPR |
| cAMP | Cyclic adenosine monophosphate |
| CB | Citrate buffer |
| Cmpd17b | Compound 17b, agonist of FPR1/2 |
| Cmpd43 | Compound 43, agonist of FPR1/2 |
| COX 1 | Cyclooxygenase-1 |
| COX 2 | Cyclooxygenase-2 |
| Cq | Quantification cycle |
| DMSO | Dimethyl sulfoxide |
| EDH | Endothelium-derived hyperpolarization |
| Emax | Maximum contraction |
| ERK1/2 | Extracellular signal-regulated kinases 1/2 |
| FPR | Formyl peptide receptor family |
| FPR1 | Formyl peptide receptor 1 |
| FPR2 | Formyl peptide receptor 2 |
| Glibenclamide | ATP-sensitive potassium (KATP) channel blocker |
| HbA1c | Glycated haemoglobin A1c |
| IKca | Intermediate conductance calcium-activated potassium channel |
| KCaB | Combination of inhibitors (Apamin and TRAM34) |
| Indo | Indomethacin |
| L-NAME | nitric oxide synthase (NOS) inhibitor, L-NG-Nitroarginine methyl ester |
| LxA4 | Lipoxin 4 |
| NGS | Normal goat serum |
| Nifedipine | Calcium channel blocker |
| NO | Nitric oxide |
| NOS | Nitric oxide synthase |
| ODQ | Soluble guanylate cyclase inhibitor, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one |
| PBS | Phosphate buffered saline |
| pEC50 | Sensitivity |
| PGI2 | Prostacyclin |
| PSS | Physiological saline solution |
| PTGIR | Prostaglandin I2 receptor |
| PTGIS | Prostacyclin synthase |
| Rn18s | 18s Ribosomal RNA |
| Rmax | Maximum relaxation |
| SKca | Small conductance calcium-activated potassium channel |
| SNP | Sodium nitroprusside |
| STZ | Streptozotocin |
| TRAM34 | Intermediate conductance calcium-activated potassium channel inhibitor, 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole |
| U46619 | Thromboxane A2 mimetic |